Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Medical cannabis

Cannabis trade body will also focus on clinical trials

The Centre for Medicinal Cannabis (CMC) has announced plans to extend its remit to focus on clinical trials.

The CMC, which describes itself as an industry advocacy group and think tank, said its plans to “actively engage industry players” in clinical trials focusing on childhood epilepsy and “all other non-paediatric potential deployments of cannabis, would help boost learning and accelerate patient access to medicines, as well as market authorisation for cannabis-based medical products.

The announcement comes after Dame Sally Davies, chief medical officer for England, told MPs that clinical trials were the only way to get medical cannabis products licenced; she called on industry to take the lead and also to fund them.

The CMC said it wanted to expand its original remit — which focused on policy, research and advocacy — to now include accelerating clinical trials, shaping future regulation of products and to promote clinical education.

Making the announcement, Steve Moore, its strategic counsel, said: “This immediately strengthens the CMC’s capacity to shape the future of medicinal cannabis in the UK.

“We have adopted a ‘whole equation’ approach and will now be able to contribute across the spectrum of public policy, clinical research, medical education and public advocacy across all areas of regulation and law governing both high-THC unlicensed medicines … and cannabidiol products available without prescription to UK consumers.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206418

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.